It's become almost a cliche' in the past decade that for many tests, Medicare coverage will occur ahead of most commercial insurance coverage. Or, areas like minimal residual disease (MRD) or comprehensive genomic profiling (CGP; CMS NCD 90.2), Medicare coverage will be broader.
This 15-page white paper was written entirely by Chat GPT, which was given only a few sentences of initial guidance (prompt shown on page 12). Therefore, it should be taken as an example of the current state of AI planning, research, organization, and writing - rather than a a truth standard or as a reference article.
Find the white paper here.
Medicare has repeatedly moved first in advanced oncology genomics: nationally for FDA-linked comprehensive sequencing and locally through MolDX for tumor-informed MRD. Commercial coverage remains fragmented, with several national policies still negative and only positive outliers. Evidence, guidelines, FDA labels, and contracting—not analytic performance alone—will determine the next wave.
Executive Summary
This white paper finds an ongoing gap
between Medicare and commercial insurance in advanced oncology genomics. Almost ten years ago, 2018, CMS NCD 90.2 created national coverage for qualifying FDA-approved or cleared
next-generation sequencing companion diagnostics in advanced cancer and
preserved contractor discretion for additional tests. That framework was far more
permissive than commercial policies of the day. The pattern recurred in molecular
residual disease: MolDX established a test-and-indication pathway enabling
broad Signatera coverage --while several major commercial policies continued to
classify solid-tumor MRD as unproven, investigational, or not medically
necessary.
The 2026 sample is fragmented rather than
uniformly negative. UnitedHealthcare, Aetna, Cigna, Carelon-administered plans,
the Federal Employee Program, and Excellus remain adverse; Blue Shield of
California is unusually expansive; Centene covers selected Signatera uses; and
Arkansas Blue Cross covers a narrow Merkel-cell indication. This dispersion
reflects different evidentiary thresholds, especially the gap between "prognostic validity" and actual proof that test-directed management improves outcomes.
Commercial convergence is likely to proceed no faster than indication by indication. FDA’s 2026 Signatera companion-diagnostic approval in muscle-invasive bladder cancer and guideline changes may accelerate that use first. Laboratories should fund prospective utility trials, pursue regulatory and guideline milestones, constrain testing cadence, and build payer-specific economic evidence. Early movers have a moat, part of which is data, but part of which is the high level of payer resistance.
